BackBrowsing by Author "Arretxe Oliden, Enara"
Now showing items 1-7 of 7
-
A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma
; ; ; ; ; ; ; ; ; ; Ávila, Matías A.
; ; ; Bujanda Fernández de Pierola, Luis ; Bañales Asurmendi, Jesús María ; (MDPI, 2020-05-31)
The diagnosis of adenocarcinomas located in the pancreas head, i.e., distal cholangiocarcinoma (dCCA) and pancreatic ductal adenocarcinoma (PDAC), constitutes a clinical challenge because they share many symptoms, are not ... -
Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD
Marques, Vanda; Afonso, Marta Bento; Bierig, Nina; Duarte-Ramos, Filipa; Santos Laso, Álvaro; Jiménez Agüero, Raúl; Eizaguirre Letamendia, Emma; Bujanda Fernández de Pierola, Luis; Pareja Megía, María J.; Luís, Rita; Costa, Adília; Machado, Mariana Verdelho; Alonso, Cristina; Arretxe Oliden, Enara; Alustiza Echeberria, José María; Krawczyk, Marcin; Lammert, Frank; Tiniakos, Dina G.; Flehmig, Bertram; Cortez-Pinto, Helena; Bañales Asurmendi, Jesús María ; Castro, Rui E.; Normann, Andrea; Rodrigues, Cecilia M. P. (Frontiers Media, 2021-06-23)
[EN] Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease where liver biopsy remains the gold standard for diagnosis. Here we aimed to evaluate the role of circulating adiponectin, ... -
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Martínez de Marigorta Izaga, Edorta; ; ; ; ; ; ; ; ; ; Bañales Asurmendi, Jesús María ; ; ; ; ; ; ; ; ; ; (Wiley, 2022-10)
Background and Aims We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. Approach and ... -
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
Afonso, Marta Bento; Rodrigues, Pedro M.; Mateus Pinheiro, Miguel; Simao, André L.; Gaspar, María M.; Majdi, Amine; Arretxe Oliden, Enara; Alonso, Cristina; Santos Laso, Álvaro; Jiménez Agüero, Raúl; Eizaguirre Letamendia, Emma; Bujanda Fernández de Pierola, Luis; Pareja Megía, María J.; Bañales Asurmendi, Jesús María ; ratziu, Vlad; Gautheron, Jeremie; Castro, Rui E.; Rodrigues, Cecilia M. P. (BMJ, 2021-12)
[EN]Objective Receptor-interacting protein kinase 3 (RIPK3) is a key player in necroptosis execution and an emerging metabolic regulator, whose contribution to non-alcoholic fatty liver disease (NAFLD) is controversial. ... -
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis
Bañales Asurmendi, Jesús María; ; ; ; ; ; ; ; ; ; ; ; ; Ávila, Matías A. ; Martínez Chantar, María Luz ; Bujanda Fernández de Pierola, Luis ; ; ; (Wiley, 2019-08)
Early and differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) by noninvasive methods represents a current clinical challenge. The analysis of low-molecular-weight metabolites ... -
SREBP-2-driven transcriptional activation of human SND1 oncogene
Armengol López, Sandra; Arretxe Oliden, Enara; Enzunza, Leire; Llorente, Irati; Mendibil, Unai; Navarro Imaz, Hiart; ; Chico Carmona, Yolanda; Martínez San Pelayo, María José (Impact Journals LLC, 2017-12-08)
Upregulation of Staphylococcal nuclease and tudor domain containing 1 (SND1) is linked to cancer progression and metastatic spread. Increasing evidence indicates that SND1 plays a role in lipid homeostasis. Recently, it ... -
The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Bañales Asurmendi, Jesús María; Andersen, Jesper B. (Elsevier, 2021-11)
[EN]Background: Non-alcoholic fatty liver disease (NAFLD) is affecting more people globally. Indeed, NAFLD is a spectrum of metabolic dysfunctions that can progress to hepatocellular carcinoma (NAFLD-HCC). This development ...